FreeNo sign-upNo subscriptionNo affiliate links
Dihexa is a peptidomimetic engineered from angiotensin IV for oral activity in preclinical models. It has never been tested in a human clinical trial, so this page computes only what a label supports: amounts per container and what each costs. The compound is covered in the Dihexa guide.
A 10 mg Dihexa container — the labelled size on the one test on file — at the lowest tracked $8.00 per mg, the same 10 mg would be $79.99. The number of amounts a container holds is its label mg ÷ the amount you enter — Dihexa has no established human dose, and this page does not supply one.
The price is the lowest tracked per milligram (a median is published from 5 shops) in the price feed now, from lyophilised or bulk offers; a capsule or tablet sells at its own price, so enter your own product's strength as the container size.
The only route the compound page names for Dihexa is oral activity in preclinical models, so this calculator prints no syringe units and offers no diluent step. It divides a labelled container by an amount you supply; no human dose exists.
Log it week by week in the free peptide tracker and check your vial's lot against lab tests on file. Private until you publish.
Dihexa has 1 independent lab test on file at Peptigrity. Purity is not net content: a clean certificate confirms what is in a vial, not how much. See the Dihexa lab-test records.
Dihexa (developmental code PNB-0408) is a small peptidomimetic derived from angiotensin IV — chemically N-hexanoyl-Tyr-Ile-(6)-aminohexanoic amide — developed at Washington State University to overcome native angiotensin IV's rapid degradation and poor brain penetration. It is peptide-derived but not a conventional peptide, and it is not an approved drug. The table below is what the compound page states, as last updated in August 2026.
| Question | What the compound page states | Evidence level |
|---|---|---|
| What is it? | An angiotensin IV-derived peptidomimetic, hexanoylated and amidated for peptidase resistance and lipophilicity | Chemical identity |
| How does it act? | Proposed to bind hepatocyte growth factor and potentiate HGF/c-Met signalling, driving hippocampal synapse formation | Preclinical (cell-based and animal) |
| Which route? | Oral activity in preclinical models — the only route named | Preclinical |
| Human evidence? | No human clinical trials as of August 2026 | Preclinical only |
| Human safety? | No established human safety profile; HGF/c-Met is also a pathway implicated in cancer biology | None |
| A dose on Peptigrity? | “No. Peptigrity is an independent review platform, not a medical authority.” | None — declined |
The compound-specific caveat is the thinness of the record. Dihexa has one independent lab test on file, from one shop and one laboratory. One test describes one batch; it says nothing about what the rest of the market ships, which is why this page reports it as a count and a measured quantity, not as a purity figure.
No dose table, because there is no human dose to tabulate: as of August 2026 every published Dihexa study is preclinical, and the compound page states there is no established human dose, efficacy or safety profile. No syringe arithmetic and no diluent step, because the only route named anywhere in Peptigrity's sources is oral activity in animal models. The compound page names no product form either, so the calculator does not ask for one.
Amounts per container = label mg ÷ your amount; cost per amount = your amount × $/mg; container cost = label mg × $/mg. The one test on file is the only measured quantity there is; the table gives it, with the difference computed here.
| Test date | Labelled | Measured | Difference | Lab |
|---|---|---|---|---|
| 22 Jul 2026 | 10 mg | 10.24 mg | +2.4% | ILS Laboratories |
That container measured 2.4% over its label. It is a single result, so it cannot be applied to any other container; the calculator works from the label on yours.
Prices: A lowest of $8.00 per mg on a 10 mg container, across 5 comparable in-stock offers from 4 shops; a median is published from 5 shops. Most Dihexa listings are kits or not sold as a vial, so the figures rest on few offers. The figures exclude shipping, taxes, coupons and kits; the listings are on the Dihexa price page.
Per the compound page, as of August 2026 no regulator has approved Dihexa for any use; it is supplied for research use only. Dihexa acetate is not on the FDA's active Category 2 “do-not-compound” list: its compounding nomination was withdrawn by the nominator, and the FDA has slated dihexa acetate for Pharmacy Compounding Advisory Committee consideration before the end of February 2027 — an advisory step that does not, by itself, make it an approved or lawfully compounded drug. Country rules: regulatory status by country.
Independent test record: Dihexa lab tests. Tracked prices: Dihexa price per milligram. The category it sits in: cognitive enhancement and neuroprotection.
There is none. As of August 2026 there are no human clinical trials of Dihexa - every published study is preclinical - and the compound page states there is no established human dose, efficacy or safety profile. Peptigrity does not recommend a dose.
It is a peptidomimetic: a small molecule derived from angiotensin IV, N-hexanoyl-Tyr-Ile-(6)-aminohexanoic amide, modified to resist peptidases and to cross the blood-brain barrier.
The only route the compound page names is oral activity in preclinical models. No human route has been studied and no injectable route is named, so this page prints no syringe units.
Thinly. There is 1 independent lab test on file, from July 2026, labelled 10 mg and measured at 10.24 mg (+2.4%). One test describes one batch, not the market, so this page does not turn it into a purity headline.
A lowest of $8.00 per mg on a 10 mg container, across 5 comparable in-stock offers from 4 shops; a median is published from 5 shops. The offers of 10 mg or less range from $8.00 to $28.00 per mg.